Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28298245 | 0.89 | OPRM1 (0.48) | OPRL1OPRM1OPRK1 | |
| SCHEMBL8666205 | 0.78 | OPRM1 (0.39) | OPRL1OPRM1OPRK1 | |
| SCHEMBL8664027 | 0.77 | OPRL1 (0.47) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3413521 | 0.75 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL8669746 | 0.74 | SLC6A2 (0.37) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3067732 | 0.73 | OPRL1 (0.62) | OPRL1OPRM1OPRK1 | |
| SCHEMBL16361263 | 0.68 | OPRL1 (0.61) | OPRL1OPRM1OPRK1 | |
| SCHEMBL1107796 | 0.67 | PNMT (0.38) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13695532 | 0.67 | OPRL1 (0.79) | OPRL1OPRM1OPRK1 | |
| SCHEMBL5031067 | 0.67 | SLC6A2 (0.38) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141674-B2 | Anti-inflammatory compounds | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1201649-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1201660-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6852719-B2 | Dietetics; antidiabetic agents; antiinflammatory agents | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040014741-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2004-01-22 | — | — | US | disclosed |
| US-6509369-B2 | Triphenylpropanamide compounds; useful in treating inflammations but which do not demonstrate side effects associated with other anti-inflammatory treatments such as glucocorticoids | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020107235-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2002-08-08 | — | — | US | disclosed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1201660-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6372779-B1 | ANTHRACENE DERIVATIVES WITH CARBAMOYL GROUPS, AMIDO GROUPS, UREA GROUPS AND SULFONAMIDE GROUPS | ORTHO PHARMACEUTICAL CORPORATION | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014741-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | OPRL1 119/4885OPRM1 318/4885OPRK1 306/4885 |
| US-20020107235-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | OPRL1 117/4885OPRM1 321/4885OPRK1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.